Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Absci Corp
(NQ:
ABSI
)
4.010
-0.130 (-3.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Absci Corp
< Previous
1
2
3
4
5
6
7
Next >
6 Analysts Assess Absci: What You Need To Know
March 22, 2024
Via
Benzinga
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023
March 21, 2024
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Absci: Q4 Earnings Insights
March 21, 2024
Via
Benzinga
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
March 21, 2024
From
Absci Corporation
Via
GlobeNewswire
The Analyst Landscape: 4 Takes On Absci
March 06, 2024
Via
Benzinga
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
March 04, 2024
Grand View Research says the global
Via
Talk Markets
Why Absci (ABSI) Shares Are Falling
February 28, 2024
Absci shares are trading lower by 9.4% Wednesday afternoon. The company announced an offering of 16.7 million shares at $4.50 per share.
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Absci
January 08, 2024
Via
Benzinga
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 01, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Pricing of Public Offering of Common Stock
February 27, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Proposed Public Offering of Common Stock
February 27, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
February 21, 2024
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
February 20, 2024
From
Absci Corporation
Via
GlobeNewswire
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
February 19, 2024
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday
February 01, 2024
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...
Via
Benzinga
iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
January 19, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
January 12, 2024
Via
Benzinga
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
January 10, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 26th Annual Needham Growth Conference
January 03, 2024
From
Absci Corporation
Via
GlobeNewswire
AI-Focused Drug Discovery Stocks Index Up 26% In December
December 29, 2023
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.
Via
Talk Markets
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
Absci Corporation
Via
GlobeNewswire
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
December 20, 2023
From
Absci Corporation
Via
GlobeNewswire
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
December 17, 2023
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 26, 2023
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth...
Via
Benzinga
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
December 11, 2023
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
December 04, 2023
Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and Development
From
Absci Corporation
Via
GlobeNewswire
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
December 04, 2023
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 15, 2023
From
Absci Corporation
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.